Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease.

Mecocci P, Polidori MC.

Biochim Biophys Acta. 2012 May;1822(5):631-8. doi: 10.1016/j.bbadis.2011.10.006. Epub 2011 Oct 13. Review.

2.

Conflict of evidence: carotenoids and other micronutrients in the prevention and treatment of cognitive impairment.

Polidori MC, De Spirt S, Stahl W, Pientka L.

Biofactors. 2012 Mar-Apr;38(2):167-71. doi: 10.1002/biof.1001. Epub 2012 Mar 15. Review.

PMID:
22419511
3.
4.

Antioxidant strategies for Alzheimer's disease.

Grundman M, Grundman M, Delaney P.

Proc Nutr Soc. 2002 May;61(2):191-202. Review.

PMID:
12133201
5.

Antioxidants for the treatment of mild cognitive impairment.

Mecocci P, Mariani E, Cornacchiola V, Polidori MC.

Neurol Res. 2004 Jul;26(5):598-602. Review.

PMID:
15265281
6.

Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum.

Mecocci P.

J Alzheimers Dis. 2004 Apr;6(2):159-63. Review.

PMID:
15096699
7.

Selenium and Alzheimer's disease: a systematic review.

Loef M, Schrauzer GN, Walach H.

J Alzheimers Dis. 2011;26(1):81-104. doi: 10.3233/JAD-2011-110414. Review.

PMID:
21593562
8.

Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.

Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C.

Neurosci Lett. 2010 Jan 18;469(1):6-10. doi: 10.1016/j.neulet.2009.11.033. Epub 2009 Nov 13.

PMID:
19914330
9.

Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.

Levey A, Lah J, Goldstein F, Steenland K, Bliwise D.

Clin Ther. 2006 Jul;28(7):991-1001. Review.

PMID:
16990077
10.

Antioxidant approaches for the treatment of Alzheimer's disease.

Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee HG, Perry G.

Expert Rev Neurother. 2010 Jul;10(7):1201-8. doi: 10.1586/ern.10.74. Review.

PMID:
20586698
11.

The status of ongoing trials for mild cognitive impairment.

Sramek JJ, Veroff AE, Cutler NR.

Expert Opin Investig Drugs. 2001 Apr;10(4):741-52. Review.

PMID:
11281823
12.

Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease.

Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR.

J Alzheimers Dis. 2008 Sep;15(1):117-28.

PMID:
18780972
13.

Current status of antioxidant therapy for Alzheimer's Disease.

Pitchumoni SS, Doraiswamy PM.

J Am Geriatr Soc. 1998 Dec;46(12):1566-72. Review.

PMID:
9848820
14.

Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows.

Praticò D.

Ann N Y Acad Sci. 2008 Dec;1147:70-8. doi: 10.1196/annals.1427.010. Review.

PMID:
19076432
15.

[Oxidative stress in the pathogenesis of Alzheimer's disease and antioxidant neuroprotection].

Behl C, Holsboer F.

Fortschr Neurol Psychiatr. 1998 Mar;66(3):113-21. Review. German.

PMID:
9565761
16.

Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease.

Calabrese V, Butterfield DA, Stella AM.

Ital J Biochem. 2003 Dec;52(4):177-81. Review.

PMID:
15141484
17.

Oxidative stress hypothesis in Alzheimer's disease: a reappraisal.

Praticò D.

Trends Pharmacol Sci. 2008 Dec;29(12):609-15. doi: 10.1016/j.tips.2008.09.001. Epub 2008 Oct 4. Review.

PMID:
18838179
18.

Mild cognitive impairment and preclinical Alzheimer's disease.

Morris JC.

Geriatrics. 2005 Jun;Suppl:9-14. Review.

PMID:
16025770
19.

Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.

Hager K, Kenklies M, McAfoose J, Engel J, Münch G.

J Neural Transm Suppl. 2007;(72):189-93.

PMID:
17982894
20.

Antioxidant pathways in Alzheimer's disease: possibilities of intervention.

Viña J, Lloret A, Giraldo E, Badia MC, Alonso MD.

Curr Pharm Des. 2011 Dec;17(35):3861-4. Review.

PMID:
21933145
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk